Drug Trial Radar · NCT06004128
Provide Pre-approval Single-patient Expanded Access (Compassionate Use) of VYD222 for Patients With Symptomatic COVID-19 Refractory to Other Treatments
Last checked: Nov 19, 2026Latest source record: Jun 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
No longer available
Enrollment
Not stated
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- Invivyd, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 22, 2023
Design
- Study type
- Expanded access
- Who can join
- All sexes
Summary
As written by the sponsor on the registry.
Provide pre-approval single-patient Expanded Access (Compassionate Use) of VYD222 for patients with symptomatic COVID-19 refractory to other treatments.
Conditions
- COVID-19
Interventions
VYD222Drug
Monoclonal antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.